Skip to main content

Market Overview

Tesaro Shares Lower On Receipt Of FDA Complete Response Letter

Share:
Tesaro Shares Lower On Receipt Of FDA Complete Response Letter

On Wednesday, TESARO Inc (NASDAQ: TSRO) announced it had received a complete response letter from the FDA for its candidate, Varubi, in chemotherapy-induced nausea and vomiting.

Leerink’s Seamus Fernandez maintains an Outperform rating on the company.

Temporary Setback

According to Tesaro’s press release, the FDA “requested additional information regarding the in vitro method utilized to demonstrate comparability of drug product produced at the two proposed commercial manufacturers for rolapitant IV that were included in the NDA.”

The company also stated that the FDA did not express any concerns regarding the efficacy or safety of Varubi, an IV formulation, and that further clinical trials had not been requested.

Fernandez believes this is only a temporary setback for Tesaro and that management expects to able to address the issue in a timely manner to gain approval in the first half of 2017.

Peak Estimates Maintained

“Ultimately, investor focus remains predominantly on the company's PARP inhibitor niraparib and we continue to expect a broad label for second-line or greater ovarian cancer maintenance by the PDUFA date of 6/30/17,” the analyst said.

Expecting a speedy response to the FDA’s CRL, Fernandez does not expect any significant impact to the peak Varubi estimates of worldwide sales of $343 million by 2026, with a majority of the sales coming from the United States.

At its peak, Varubi is expected to capture 35 percent share of the U.S. market and 25 percent of the EU NK-1 market, and for the IV formulation to witness 85 percent sales in the United States, with 20 percent coming from the EU.

At last check, shares of Tesaro were down 2.33 percent at $142.50.

Latest Ratings for TSRO

DateFirmActionFromTo
Dec 2018BarclaysDowngradesOverweightEqual-Weight
Dec 2018WedbushDowngradesOutperformNeutral
Dec 2018GuggenheimDowngradesBuyNeutral

View More Analyst Ratings for TSRO
View the Latest Analyst Ratings

 

Related Articles (TSRO)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas News Eurozone Health Care Reiteration FDA Best of Benzinga

Latest Ratings

StockFirmActionPT
GOOGLMizuhoMaintains2,600.0
VZIOWells FargoInitiates Coverage On31.0
TWTROppenheimerMaintains85.0
SBUXOppenheimerMaintains135.0
OMWells FargoInitiates Coverage On63.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com